Partial seizures, which are the most common type of seizures in adults, may be characterized by impaired consciousness, loss of awareness, involuntary motor behaviors, and other non-conscious, involuntary events. For physicians and patients, the attraction of Keppra is that it increases seizure control without adverse interaction with co-administered antiepileptic drugs.
Epilepsy is caused by excessive electrical activity in the brain.
All of the 1393 epilepsy patients who participated in the trials had continued to experience seizures during the baseline period despite their being treated with 1-2 antiepileptic drugs. Concomitant AED regimens were held constant during administration of Keppra. Effectiveness of the Keppra therapy was measured primarily by reduction in weekly partial seizure frequency for the entire treatment period. Results of the trials indicated that Keppra significantly reduces the weekly seizure frequency over a placebo. In general, higher doses yielded greater reduction in number of seizures, although results varied over trials.